Daxor
DXR
6 hedge funds and large institutions have $974K invested in Daxor in 2025 Q2 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
24% more capital invested
Capital invested by funds: $785K → $974K (+$189K)
0.06% more ownership
Funds ownership: 2% → 2.06% (+0.06%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
14% less funds holding
Funds holding: 7 → 6 (-1)
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$28.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$2.65K |
| 2 |
Renaissance Technologies
New York
|
-$811 |
DXR Hedge Fund Activity: Q2 2025 in Review
6 of the 7,604 institutional investors tracked by Wall St. Rank reported a position in Daxor (DXR) for Q2 2025, worth a combined $974K — up 24% from $785K a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of DXR and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 1 added.
The largest buyer was Morgan Stanley, adding an estimated $28.1K. The largest seller was UBS Group, exiting entirely with an estimated $2.65K sold.
- 6 institutional investors held Daxor (DXR) as of Q2 2025, down from 7 in Q1 2025.
- Funds reported $974K of Daxor stock for Q2 2025, up 24% quarter-over-quarter.
- 0 funds opened new Daxor positions in Q2 2025 and 1 closed out, a net change of -1 holder.
- The largest Daxor buyer in Q2 2025 was Morgan Stanley, an estimated $28.1K added.
- The largest Daxor seller in Q2 2025 was UBS Group, an estimated $2.65K sold.
Based on aggregated 13F filings for Q2 2025.